Business Description
Durata Therapeutics Inc
ISIN : US26658A1079
Compare
Compare
Traded in other countries / regions
DTA.Germany Description
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.55 | |||||
| Equity-to-Asset | -0.2 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.36 | |||||
| Quick Ratio | 1.26 | |||||
| Days Sales Outstanding | 6.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 100 | |||||
| Operating Margin % | -679.94 | |||||
| Net Margin % | -730.11 | |||||
| FCF Margin % | -438.58 | |||||
| ROE % | -375.05 | |||||
| ROA % | -81.97 | |||||
| ROIC % | -1000.74 | |||||
| ROC (Joel Greenblatt) % | -6588.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 63.58 | |||||
| EV-to-Revenue | 66.76 | |||||
| Earnings Yield (Greenblatt) % | -10.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Durata Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.823 | ||
| EPS (TTM) (€) | -2.046 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 7.49 - 19.48 | ||
| Shares Outstanding (Mil) | 26.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Durata Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Durata Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Durata Therapeutics Inc Frequently Asked Questions
What is Durata Therapeutics Inc(FRA:DTA)'s stock price today?
The current price of FRA:DTA is €18.88. The 52 week high of FRA:DTA is €19.48 and 52 week low is €7.49.
When is next earnings date of Durata Therapeutics Inc(FRA:DTA)?
The next earnings date of Durata Therapeutics Inc(FRA:DTA) is .
Does Durata Therapeutics Inc(FRA:DTA) pay dividends? If so, how much?
Durata Therapeutics Inc(FRA:DTA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers